Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Levomecor Inc.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Body mass index (BMI) between 18.0 and 35.0 kg/m2.
Diagnosed with Major Depressive Disorder (MDD) based on Structured Clinical Interview for DSM-5 (SCID-5) for MDD.
Current Major Depressive Episode (MDE).
Treated on approved, stable first-line anti-depressant therapy with inadequate response to 1 to 3 valid courses of treatment with a depressant medication in the current MDE.
You may not be if
Any current and primary psychiatric disorder other than Major Depressive Disorder.
Severe alcohol or substance use disorder.
History of bipolar I and II disorder, psychosis, and/or mania.
Poorly controlled diabetes as defined by HbA1c \> 7.5%, despite standard care. Subjects with HbA1c \>7.5% may continue in the study if approved by the Relmada Medical Monitor.
Having received ketamine or esketamine within 60 days prior to Screening.
Clareo Health | A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
